Single‐domain antibodies and their utility

TN Baral, R MacKenzie… - Current protocols in …, 2013 - Wiley Online Library
TN Baral, R MacKenzie, M Arbabi Ghahroudi
Current protocols in immunology, 2013Wiley Online Library
Engineered monoclonal antibody fragments have gained market attention due to their
versatility and tailor‐made potential and are now considered to be an important part of future
immunobiotherapeutics. Single‐domain antibodies (sdAbs), also known as nanobodies, are
derived from VHHs [variable domains (V) of heavy‐chain‐only antibodies (HCAb)] of
camelid heavy‐chain antibodies. These nature‐made sdAbs are well suited for various
applications due to their favorable characteristics such as small size, ease of genetic …
Abstract
Engineered monoclonal antibody fragments have gained market attention due to their versatility and tailor‐made potential and are now considered to be an important part of future immunobiotherapeutics. Single‐domain antibodies (sdAbs), also known as nanobodies, are derived from VHHs [variable domains (V) of heavy‐chain‐only antibodies (HCAb)] of camelid heavy‐chain antibodies. These nature‐made sdAbs are well suited for various applications due to their favorable characteristics such as small size, ease of genetic manipulation, high affinity and solubility, overall stability, resistance to harsh conditions (e.g., low pH, high temperature), and low immunogenicity. Most importantly, sdAbs have the feature of penetrating into cavities and recognizing hidden epitopes normally inaccessible to conventional antibodies, mainly due to their protruding CDR3/H3 loops. In this unit, we will present and discuss comprehensive and step‐by‐step protocols routinely practiced in our laboratory for isolating sdAbs from immunized llamas (or other members of the Camelidae family) against target antigens using phage‐display technology. Expression, purification, and characterization of the isolated sdAbs will then be described, followed by presentation of several examples of applications of sdAbs previously characterized in our laboratory and elsewhere. Curr. Protoc. Immunol. 103:2.17.1‐2.17.57. ©2013 by John Wiley & Sons, Inc.
Wiley Online Library